(Q45023986)

English

Asbestos fibres inhibit the in vitro activity of ymphokine-activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma

scientific article published on January 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 December 2017

Asbestos fibres inhibit the in vitro activity of ymphokine-activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma (English)

reason for preferred rank

most precise value

1 reference

10.1111/J.1365-2249.1991.TB05593.X

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05593.X

8 December 2022

Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1846329

8 December 2022

1 reference

based on heuristic

inferred from title

1 reference

10.1111/J.1365-2249.1991.TB05593.X

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05593.X

8 December 2022

author name string

L. S. Manning

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1846329

8 December 2022

M. R. Davis

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1846329

8 December 2022

B. W. Robinson

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1846329

8 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1846329

8 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

8 December 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2249.1991.tb05593.x

1 reference

10.1111/J.1365-2249.1991.TB05593.X

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05593.X

8 December 2022

https://academic.oup.com/cei/article-pdf/83/1/85/42217005/j.1365-2249.1991.tb05593.x.pdf

Portable Document Format

1 reference

10.1111/J.1365-2249.1991.TB05593.X

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05593.X

8 December 2022

Clinical and Experimental Immunology

1 reference

Europe PubMed Central

8 December 2017

83

1 reference

Europe PubMed Central

8 December 2017

1

1 reference

Europe PubMed Central

8 December 2017

85-91

1 reference

Europe PubMed Central

8 December 2017

The pathogenesis of asbestos-associated diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1991.TB05593.X

21 January 2018

Immunologic investigations in asbestos-exposed workers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1991.TB05593.X

21 January 2018

Effects of Asbestos and Beryllium on Release of Alveolar Macrophage Enzymes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1991.TB05593.X

21 January 2018

Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1991.TB05593.X

21 January 2018

Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1991.TB05593.X

21 January 2018

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1991.TB05593.X

21 January 2018

Current pathogenetic concepts of diffuse malignant mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological studies of patients with asbestosis. I. Studies of cell-mediated immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topographic distribution of asbestos fibres in human lung in relation to occupational and non-occupational exposure

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of in vitro asbestos exposure on natural killer and antibody-dependent cellular cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Asbestos-associated chromosomal changes in human mesothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impairments in functional subsets of T-suppressor (CD8) lymphocytes, monocytes, and natural killer cells among asbestos-exposed workers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pleural mesothelial cells stimulated by asbestos release chemotactic activity for neutrophils in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of cancer with activated lymphocytes and interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune responses in asbestos-exposed individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced killer cell activity of lymphocytes from patients with asbestosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum interferon levels and natural killer cell activity in patients with asbestosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of chrysotile and crocidolite asbestos on the lower respiratory tract: Analysis of bronchoalveolar lavage constituents

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fiber size and number in amphibole asbestos-induced mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fiber counting and analysis in the diagnosis of asbestos-related disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diminished suppressor cell function in patients with asbestosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced interleukin activity following asbestos inhalation

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition of a "trigger" stage in the NK cytolytic reaction sequence by a monoclonal antibody to the glycoprotein T-200.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cell activity in asbestos workers. Interactive effects of smoking and asbestos exposure

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cell activity in cigarette smokers and asbestos workers

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological studies of patients with asbestosis. II, Studies of circulating lymphoid cell numbers and humoral immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1846329

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.

27

1 reference

10.1111/J.1365-2249.1991.TB05593.X

https://api.crossref.org/works/10.1111/J.1365-2249.1991.TB05593.X

8 December 2022

Identifiers

10.1111/J.1365-2249.1991.TB05593.X

1 reference

Europe PubMed Central

8 December 2017

0 references

1 reference

Europe PubMed Central

8 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45023986&oldid=1787121610"